Company Overview and News

 
UPDATE 1-Lowe's names J.C. Penney's Marvin Ellison as CEO

28m reuters
(Reuters) - Home improvement chain Lowe’s Cos Inc (LOW.N) on Tuesday named J.C. Penney’s (JCP.N) Chief Executive Officer Marvin Ellison to the top position, replacing Robert Niblock.

 
JC Penney's CEO Ellison departs for Lowe's, shares plunge

29m nzherald.co.nz
MOORESVILLE, N.C. (AP) — J.C. Penney's CEO is leaving the company to become the top executive at Lowe's.

 
Is A Storm Brewing For Lowe's Earnings Wednesday?

40m seekingalpha
We map and analyze the exposure of Home Depot and Lowe's stores to severe winter weather last quarter.

 
Home Depot: Price Trajectory Uncertain, But I Would Still Go Long

1h seekingalpha
However, this company continues to perform very strongly from a free cash flow and dividend growth perspective.

1
HD / Home Depot, Inc. (The) 10-Q (Quarterly Report)

3h sec.gov
Document Table of Contents

 
Dividend Sensei's Portfolio Update 35: If You Want To Get Rich, Follow The Data

7h seekingalpha
There is much debate in the world of investing about how to build a portfolio to meet your long-term needs.

 
Monro's (MNRO) CEO Brett Ponton Hosts Investor Day (Transcript)

16h seekingalpha
Good morning, everyone. And welcome to the Monro’s Investor Day. My name is Maureen Mulholland. I am Senior Vice President, General Counsel, and Secretary at Monro. I’d like to thank everyone for joining us here in person, as well as those of you listening via webcast. We’re excited to be hosting our first Investor Day and we appreciate your time this morning.

 
Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo

20h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Procter & Gamble (PG), AbbVie (ABBV), McDonald’s (MCD) and PepsiCo (PEP). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

 
Factors Setting the Tone for Lowe's (LOW) in Q1 Earnings

2018-05-21 zacks
Lowe's Companies, Inc. (LOW - Free Report) is scheduled to report first-quarter fiscal 2018 results on May 23. In the preceding quarter, the company’s earnings lagged the Zacks Consensus Estimate by 15.9%. This home improvement retailer failed to beat the consensus mark in the trailing four quarters, the average being a negative 4.9%.

 
Market Strategy for the Week: China and Retail Stocks

2018-05-21 marketrealist
The Trump Administration basically said it was going to suspend its pending trade war with China as a deal gets worked out. Further, they believe that part of that deal will include China buying more energy and agriculture products from the U.S. No further numbers were thrown around after a $200 billion deficit reduction was suggested late last week. This is good news, even if the early indications are only that agriculture and energy (USO) will be the big beneficiaries, it could suggest what we have been hoping for: a de-escalation of tariff and trade-war risks.

 
Home Depot: With Expected 28% EPS Growth In FY18, Mr. Market Is Short-Sighted

2018-05-21 seekingalpha
Home Depot's total return outperformed the Dow average for my 52.0-month test period by 96.03%, which is great for this building supply retailer.

 
Home Depot: With Expected 28% EPS Grow In FY18, Mr. Market Is Short-Sighted

2018-05-21 seekingalpha
Home Depot's total return outperformed the Dow average for my 52.0-month test period by 96.03%, which is great for this building supply retailer.

 
Walmart: This Normalization Period Will Last

2018-05-18 seekingalpha
After a red-hot 2017, shares of big box retailer Walmart (WMT) have cooled down considerably in 2018. WMT stock is down 15% YTD and nearly 25% off its early January highs. Unfortunately, recent quarterly numbers support the thesis that this normalization era in WMT stock will persist into the foreseeable future. The reality of the situation is that WMT got way ahead of itself in 2017 due to unrealistically bullish expectations for super-charged digital commerce growth.

 
25 Most Popular Stores in America

2018-05-18 247wallst
Consumer spending is the primary driver of economic growth in the United States. After climbing for eight consecutive years, U.S. consumer spending hit an all-time high of $13.4 trillion in 2017.

 
Boeing, Caterpillar Prop Up the Dow Thursday

2018-05-18 247wallst
May 18, 2018: Markets opened lower again Friday and while the Dow hugged the break-even line all day, the S&P 500 and the Nasdaq Composite remained in the red for the entire trading session. U.S. trade talks with China have hit a bump in the road and negotiations with Mexico and Canada on revisions to NAFTA missed a deadline of sorts Thursday. Friday’s best performing sector was industrials, probably thanks to Deere & Co.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

19h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 437076102